Karuna Therapeutics, Inc. (KRTX) Reports KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Karuna Therapeutics Inc. (KRTX) Climbs 30%
November 19, 2019 10:36 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Climbs 30%
... MoreKaruna Therapeutics Inc. (KRTX) Halted on LUDP
November 19, 2019 10:18 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP
... MoreKaruna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock
November 18, 2019 4:22 PM ESTKaruna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000... More
Karuna Therapeutics Inc. (KRTX) Halted on LUDP, Up 230%
November 18, 2019 9:53 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP, Up 230%
... MoreKaruna Therapeutics Inc. (KRTX) Extends Gain, Up 175%
November 18, 2019 9:47 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Extends Gain, Up 175%
... MoreKaruna Therapeutics Inc. (KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
November 18, 2019 7:17 AM ESTKaruna Therapeutics (NASDAQ: KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
... More